Xynomic pharmaceuticals holdings, inc. (XYN)
Balance Sheet / TTM
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Dec'16
ASSETS
Current assets:
Cash

27

1,191

3

4,746

146

317

142

210

248

571

298

Prepaid expenses

205

155

15

277

54

82

67

89

108

24

0

Founder subscription receivable

-

-

-

-

-

-

-

-

0

0

25

Total current assets

232

1,347

18

5,024

201

400

210

299

356

595

323

Property and equipment, net

276

444

-

280

-

-

-

-

-

-

-

Intangible assets, net

1

1

8,477

1

62,954

62,666

62,409

62,208

62,061

61,873

0

Other non-current assets

228

219

-

155

-

-

-

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

0

0

229

TOTAL ASSETS

738

2,013

8,495

5,461

63,156

63,066

62,620

62,507

62,417

62,469

552

LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT
Current liabilities:
Bank overdraft

9

2

-

4

-

-

-

-

-

-

-

Accrued expenses and other current liabilities

19,595

16,089

-

14,407

-

-

-

-

-

-

-

Convertible promissory note - related party

-

-

500

-

-

-

-

-

-

-

-

Promissory note - related party

404

404

110

-

400

400

-

-

0

0

300

Accounts payable and accrued expenses

-

-

227

-

104

94

115

78

54

30

0

Accrued offering costs

-

-

-

-

-

-

-

-

-

-

142

Amount due to shareholders

580

552

1

3,233

1

1

1

1

1

1

87

Total current liabilities

20,590

17,048

839

17,645

505

496

117

80

56

32

529

Total liabilities

20,590

17,048

-

17,645

-

-

-

-

-

-

-

Commitments and Contingencies

-

-

-

-

0

0

0

-

0

0

0

Mezzanine equity:
Total mezzanine equity

-

-

2,656

7,910

57,650

57,570

57,502

57,427

57,361

57,436

0

Shareholders' deficit:
Preferred Stock (par value US$0.0001 per share as of December 31, 2018 and September 30, 2019; 50,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2018 and September 30, 2019

-

-

-

-

0

0

0

-

0

0

0

Common stock (par value US$0.0001 per share as of December 31, 2018 and September 30, 2019; 200,000,000 shares authorized, 8,165,377 and 46,273,846 shares issued and outstanding as of December 31, 2018 and September 30, 2019, respectively)

4

4

4,636

0

4,819

4,900

4,967

5,043

5,109

5,033

25

Additional paid-in capital

36,569

36,401

-

14,169

-

-

-

-

-

-

-

Accumulated other comprehensive income

70

77

-

58

-

-

-

-

-

-

-

Accumulated deficit

-56,496

-51,519

363

-34,323

180

99

32

-43

-109

-33

-1

Total shareholders' deficit

-19,852

-15,035

5,000

-20,094

5,000

5,000

5,000

5,000

5,000

5,000

23

TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT

738

2,013

8,495

5,461

63,156

63,066

62,620

62,507

62,417

62,469

552

Angel Preferred Shares [Member]
Preferred Shares

-

-

-

580

-

-

-

-

-

-

-

Series A Preferred Stock [Member]
Preferred Shares

-

-

-

4,905

-

-

-

-

-

-

-

Series B Preferred Stock [Member]
Preferred Shares

-

-

-

2,424

-

-

-

-

-

-

-